Downregulation of miR-21 increases cisplatin sensitivity of non-small-cell lung cancer

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Plasma miR-21 is a known biomarker for lung cancer chemotherapy response.
• The specific role of miR-21 in non-small-cell lung cancer (NSCLC) sensitivity to cisplatin (DDP) remains unconfirmed.

Purpose of the Study:

• To investigate the influence of miR-21 on NSCLC sensitivity to DDP both in vitro and in vivo.
• To evaluate the potential of targeting miR-21 to overcome DDP resistance in NSCLC.

Main Methods:

• Real-time quantitative PCR to measure miR-21 expression in lung cancer cell lines.
• Transfection of locked nucleic acid (LNA) anti-miR-21 into A549 cells and pre-miR-21 into SK-MES-1 cells.
• In vitro assays assessing cell growth, colony formation, and apoptosis.
• In vivo studies using BALB/c nude mice to evaluate DDP sensitivity after miR-21 downregulation.

Main Results:

• miR-21 expression was notably higher in A549 cells compared to other tested lung cancer cell lines.
• LNA-mediated miR-21 knockdown inhibited A549 cell growth and induced apoptosis.
• Overexpression of miR-21 in SK-MES-1 cells promoted cell growth and reduced cell death.
• Suppression of miR-21 sensitized A549 cells to DDP in vivo.

Conclusions:

• miR-21 plays a significant role in regulating NSCLC sensitivity to DDP.
• Targeting miR-21, through suppression, can enhance the efficacy of DDP treatment in NSCLC.
• These findings suggest miR-21 as a potential therapeutic target for improving DDP chemotherapy in NSCLC.